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Abstract
Purpose: Cancer genetics has emerged as a critical specialty within the field of genetic
counseling. Advancements in research are constantly uncovering new insights into the
genetics of cancer and inherited cancer syndromes. It is crucial that genetic counselors
and the institutions in which they work are in sync with these advancements. Currently,
multiplex or multi-gene cancer testing is rapidly being adapted into the cancer genetic
counseling setting. The ‘hot topic’ of an increased likelihood of receiving variant results
following such testing has been explored in depth in the literature. However, research
surrounding genetic counseling practices and the reclassification of VUS results is
lacking. No consensus guidelines addressing variant reclassification yet exist. This study
aimed to identify current practices of genetic counselors with regard to variant
reclassification, and to explore whether genetic counselors feel they need official
guidelines relating to the reclassification of variant results.
Method: An online survey distributed through the National Society of Genetic
Counselors and the Cancer Special Interest Group (SIG) was utilized in this research
study. Statistical Analysis System (SAS) 9.4 was employed for quantitative data and
statistical analysis while qualitative data was coded and analyzed for major themes using
grounded theory methods.
Results: We determined that cancer genetic counselors are handling the reclassification
of VUS results in a unified manner. Common themes across almost 200 respondents
demonstrated that they approach benign or deleterious reclassification in a similar

v

fashion. 95% of respondents (n = 209) discuss variant reclassification with their patients
upon receiving a VUS result. Similarly, 95% of respondents (n = 209) will sometimes or
always make a plan to communicate VUS reclassification results should they arise in the
future. The overwhelming majority (97%) of respondents (n = 183) indicated that the
protocol for re-contacting patients with a VUS reclassification would not be different
from what they had used in the past for single-gene analysis. Varying opinions existed on
whether practice guidelines relating to VUS reclassification are necessary. The majority,
62% of respondents (n = 178), agreed or strongly agreed that there was a need for
guidelines relating to variant reclassification. Those who disagreed expressed concerns
surrounding liability issues and the feasibility of implementing recommendations across
different institutions.
Conclusions: Findings from this study indicate that most genetic counselors are utilizing
unified practices when handling the reclassification of variant results. Additionally, a
proportion of genetic counselors felt that guidance or recommendations for certain areas
relating to variant reclassification are necessary. While future research is needed to
explore more in-depth the issues and opinions identified in this research project, another
possible approach is for the NSGC Cancer SIG to address this topic at their earliest
opportunity, given the coming wave of VUS reclassifications from multiple collaborative
efforts to more urgently reclassify VUS results.
Keywords: Cancer genetics, genetic testing, multi-gene panels, multiplex genetic
testing, variant(s), VUS, reclassification
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Chapter 1. Background
The basis of an inherited susceptibility to cancer is complex. Mutations in specific genes
can increase an individual’s risk for developing cancer (Domchek, Bradbury, Garber,
Offit, & Robson, 2013). Identifying mutations in these cancer predisposition genes is a
valuable clinical tool, as it identifies which individuals are at a particularly high risk of
developing cancer. Traditionally, it has been common practice to analyze single genes for
mutations. The genes being analyzed are those that are the most likely to carry mutations,
dependent on one’s personal and family history (Domchek et al., 2013; Mauer, PirzadehMiller, Robinson, & Euhus, 2014). If no mutation is identified, further single gene tests
may then be carried out (Domchek et al., 2013; Mauer et al., 2014). An example of this is
the traditional manner in which testing has been conducted to uncover a genetic cause for
Hereditary Breast and Ovarian Cancer (HBOC) Syndrome. Mutations in BRCA1 and
BRCA2 increase the risk for breast and ovarian cancer and are the most common genes
associated with HBOC Syndrome (Hall et al., 1990; Hilbers, Vreeswijk, van Asperen, &
Devilee, 2013; Wooster et al., 1995). HBOC syndrome was originally linked to an
autosomal dominant trait in the early 70’s and it was in the years following that BRCA1
and BRCA2 were identified (Lynch, Snyder, & Casey, 2013). Since their discovery in the
mid 1990’s, these two genes have dominated much of research and thus have led to the
recommendation of specific surgical and management interventions when a mutation is
identified (Lee & Ang, 2014; Rainville & Rana, 2014). National recommendations
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outlining surveillance options, prophylactic surgical measures and chemoprevention for
BRCA1 or BRCA2 mutation carriers exist (Pruthi, Gostout, & Lindor, 2010; Robson &
Offit, 2007).
Since the identification of BRCA1 and BRCA2, multiple other genes involved in
the same DNA repair pathway have been uncovered (Lynch et al., 2013; Rainville &
Rana, 2014). Although BRCA1 and BRCA2 remain the main players and account for the
majority of HBOC syndrome cases, other genes are now known to modify an individual’s
risk. Some examples include genes such as TP53, PTEN, NBN and STKII (Hilbers et al.,
2013; Kobayashi, Ohno, Sasaki, & Matsuura, 2013; Lynch et al., 2013; Rainville & Rana,
2014). In addition, a more recent discovery is the PALB2 gene, partner and localizer of
BRCA2. PALB2 is considered a ‘moderate risk’ susceptibility gene; if a deleterious
mutation is identified the susceptibility to breast and pancreatic cancer increases
(Hofstatter et al., 2011; Rainville & Rana, 2014; Tischkowitz et al., 2009). Some of the
cancer susceptibility genes that can, when mutated, increase an individual’s risk for either
breast and/or ovarian cancer may in fact be associated with other cancer syndromes and
not HBOC syndrome. For example, deleterious changes in the mismatch repair genes
associated with Lynch Syndrome are known to increase the risk for the development of
ovarian cancer. Despite all these advances there is undoubtedly still more to uncover and
learn about gene changes that can increase an individual’s risk to certain types of cancer.
Previously, if no mutations were identified in BRCA1 and BRCA2, it was deemed
appropriate in specific high-risk patients to carry out serial testing to investigate other
susceptibility genes. This manner of serial genetic testing can be both time consuming
and expensive (Domchek et al., 2013). Some may argue that multiplex genetic testing is
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even less economical. A study conducted by Yorczyk et al. (2014) averaged the dollar
cost of multiplex genetic testing per person from nine different laboratories and found
that offering multiplex genetic testing as a first tier approach was 21% more expensive
than conducting serial genetic testing. The panel test offered to patients as a first tier
option was the Myriad MyRisk panel that included 25 different genes. Despite this
increase in cost, authors of the study argued that multiplex genetic testing is cost effective
due to the higher detection rate and the elimination of multiple follow up clinic visits
should serial genetic testing be conducted.
In contrast to how clinical genetic testing has occurred in the past, the
improvement of sequencing techniques and the advent of next-generation sequencing
(NGS) technology has allowed for the simultaneous analysis of multiple genes (Domchek
et al., 2013; Fecteau, Vogel, Hanson, & Morrill-Cornelius, 2014; Mauer et al., 2014;
Walsh et al., 2010; Wolfe Schneider et al., 2014). Genes included on panels are
laboratory specific, but it appears there is a general concurrence about which genes
should be included (Hiraki, Rinella, Schnabel, Oratz, & Ostrer, 2014; Mauer et al., 2014).
NGS is currently the sequencing method of choice for analyzing multiple genes at the
same time. It appears that this strategy of testing multiple genes at once is becoming the
preference for many health professionals (Hiraki et al., 2014; LaDuca et al., 2014).
Importantly, the cost of multiplex genetic testing is not vastly greater than single gene
analysis (Domchek et al., 2013; Hilbers et al., 2013; Hiraki et al., 2014). Additionally,
multiplex genetic testing allows for testing in a timely manner (LaDuca et al., 2014).
High throughput NGS has allowed for much more time effective sequencing compared to
single gene analysis using Sanger sequencing (LaDuca et al., 2014; Walsh et al., 2010).
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Testing laboratories are now advertising a 2-4 week turn-around-time (TAT) for many of
their panels.
Furthermore, the use of multiplex genetic testing has allowed for individuals to be
tested for genes they may not have previously been tested for due to cost, patient fatigue
or they were considered not consistent with their personal and/or family history (LaDuca
et al., 2014; Meldrum, Doyle, & Tothill, 2011). As a result, many individuals have
received a genetic diagnosis that may not have been detected through single gene
analysis. Yorczyk et al. (2014) found that when offering a single tiered approach
(beginning with a multiplex cancer panel) the mutation detection rate increased from
3.8% to 6.7% compared to offering a panel reflexively. In their study group of 105
individuals, four mutations would not have been identified if single gene analysis were
conducted. This advanced ability has aided the implementation of a more widespread
analysis and personalized testing approach (Hiraki et al., 2014; Walsh et al., 2010). The
clinical implication of being able to rapidly test many genes at once is permeating most
subspecialties of genetic counseling, including pediatrics, cardiology, prenatal and other
areas (LaDuca et al., 2014). A specific example of NGS panels outside the cancer realm
that are becoming widely used includes panels for issues related to intellectual disability
(Mauer et al., 2014; Walsh et al., 2010).
The integration of NGS panels does, however, bring with it novel challenges such
as the increased likelihood of finding an ambiguous result, referred to as a variant of
uncertain significance or VUS (Domchek et al., 2013; Hilbers et al., 2013; Hiraki et al.,
2014; Walsh et al., 2010; Wolfe Schneider et al., 2014). A VUS is a change in sequence
for which the implication on gene function is uncertain. Therefore, risk assessment and
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management options cannot be based on the test result but rather must default to personal
and family history (Hilbers et al., 2013). For genetic counselors, old practices and
guidelines are not sufficient to deal with the complexities of multiplex genetic testing and
the results that come with them (LaDuca et al., 2014). Advances in technology have
highlighted the need for the establishment of guidelines in clinical practice.
Molecular laboratories developing cancer gene panels and carrying out testing are
continuously detecting unique, novel sequence variants (Richards et al., 2008). These
variants are typically classified within a spectrum with the American College of Medical
Genetics and Genomics (ACMG) defining different categories of sequence variation
(Richards et al., 2008; Richards et al., 2015). ACMG along with the Association for
Molecular Pathology and College of American Pathologists recently recommended the
use of a 5-tier standard terminology system (Richards et al., 2015) These categories
include the following: (1) benign; (2) likely benign; (3) uncertain significance; (4) likely
pathogenic; and (5) pathogenic (Richards et al., 2015). Additionally, ACMG recommends
that ‘likely’ be used only for variants for which there is over 90% certainty that the
variant is either benign or deleterious (Richards et al., 2015). Over time, the chance of
identifying a VUS significantly decreases, as larger data sets are available and the ability
to review and interpret variants improves (LaDuca et al., 2014; Mauer et al., 2014). For
example, Myriad reported that they have reduced the VUS rate in BRCA1 and BRCA2
from 12.8% to 2.1% over ten years during the testing of hundreds of thousands of
samples from 2002 to 2013 (Eggington et al., 2013).
A primary reason that individuals undergo genetic testing is to be able to direct
their own medical management (Vos et al., 2008). Deleterious mutations specifically
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define patient risk and may be accompanied by guidelines for management and treatment,
while VUS results may warrant risk assessment and management based more heavily on
family history (Murray, Cerrato, Bennett, & Jarvik, 2011). The National Society for
Genetic Counseling (NSGC) recommended that personal and family history and not
genetic testing results be used in order to determine medical management and
prophylactic options when an uncertain test result is received (Berliner, Fay, Cummings,
Burnett, & Tillmanns, 2013). As it is recommended that only individuals who are
considered ‘high-risk’ and have a strong family history suggestive of a cancer syndrome
undergo multiplex genetic testing, it makes sense to base any medical decisions on that
family history when genetic testing results do not provide a clear answer.
Misinterpretation or misunderstanding of a VUS result or VUS reclassification by the
physician or patient may lead to sub-optimal management of that individual.
Additionally, the National Comprehensive Cancer Network (NCCN) does not
recommend testing of other family members when a VUS is identified. Reclassification
of a VUS is therefore also critical information for other family members (Murray et al.,
2011).
Richter et al. (2013) studied both the recall of VUS results and their
interpretations. Recall is defined as bringing a fact back into one’s mind while
interpretation is related to explaining the meaning of information one has been told. In a
study conducted by Richter et al. (2013), 20% of participants were unable to correctly
recall a VUS result. Recall of results was incorrect more often in individuals with a VUS
than in individuals who had a positive or negative result. The situation was similar when
patients were asked to recall the risk associated with the VUS result. Patients categorized
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as having a VUS had the highest rate of incorrect risk recall and/or incorrect
interpretation of their VUS result. However, uptake of surgeries and surveillance was
similar to the ‘negative’ group of patients and worry associated with the risk of cancer
was similar to those who had a negative result. Vos et al. (2008) focused primarily on
how the counselee recalls and interprets a test result of uncertain significance. The
majority, 67%, was able to recall the VUS as not informative, 29% recalled it as a
pathogenic result, and 4% recalled a non-pathogenic result. However, with regard to
interpretation, 79% of participants interpreted a VUS as a predisposition to cancer while
21% interpreted it as non-informative. An additional study supported this outcome by
showing that the largest difference between recollecting what counselees were told by
their genetic counselor and how they interpreted the information was found in the group
who had a VUS communicated to them (Vos et al., 2011). Therefore, patients are at risk
of recalling a VUS result incorrectly in addition to misinterpreting the meaning of the
VUS result.
In an ever-evolving genetics world, patients are expecting to hear and discuss
genetic aspects of their disease with their primary care physicians (PCPs) (Houwink et
al., 2011; Miller et al., 2010) have shown that patients not only show genetic test results
to their PCP’s, but they seek out their advice about what to do with such results. If the
healthcare profession wants to maximize the benefit of the advances being made,
important members of the healthcare team need to be educated properly. As part of their
study Richter et al. surveyed a small cohort of family physicians (n = 21) regarding VUS
test results (2013). All physicians participating in the study would send a sibling of an
individual with a VUS for predictive genetic testing. In addition, half of the participating
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family physicians who referred patients for genetic testing never mentioned the
possibility of a VUS result. A multitude of studies have also looked at PCPs’
understanding of genetic risk, genetic testing, and appropriate referrals. Research has
suggested that in order for family physicians and PCPs to remain up to date with the
quick advances occurring in the genetic field, there is a need for improved strategies to
educate these important healthcare providers. Inevitably, this education will need to
include education about VUS results as well as reclassification.
It is feasible to see how genetic counselors can play a role in aiding the
understanding of the PCPs regarding VUS results and ensure that patients referred are
receiving appropriate care and information. However, a bigger healthcare wide
educational program or educational tools may be required.

It is imperative that a

referring physician can explain a VUS result correctly to his or her patient. In addition to
educating PCPs about test results, education about the vital importance of reclassification
and what it could mean for their patients is also critical.
Reclassification of VUS results may have important implications for a patient’s
cancer risk assessment in addition to their management options (Murray et al., 2011).
VUS reclassification is a convoluted and complicated process (Domchek & Weber, 2008;
Eggington et al., 2013). Reclassification includes constant monitoring of data in the lab,
literature review, multidisciplinary discussion, as well as searching of public databases to
continually survey for potential new variants (Eggington et al., 2013). Today, numerous
different databases and registries exist that are attempting to delineate the association
between rare, uncommon sequence variants and phenotypes. The goal of these databases
and registries is to enable clinicians and medical professionals to assess cancer risk and
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significance of VUS’s found through multiplex cancer testing. An exemplary example of
one such database is the Evidence – based Network for the Interpretation of Germline
Mutant Alleles (ENIGMA). ENIGMA is a large consortium consisting of a
multidisciplinary, international team (Spurdle et al., 2012). In January 2012, over 100
research scientists and clinicians were involved in the ENIGMA effort. Beginning in
2009, ENIGMA aimed to start interpreting variants found in BRCA1 and BRCA2 with the
hope of utilizing what has been learned to expand their efforts to other cancer
susceptibility genes, most likely beginning with PALB2 and ATM. Researchers clearly
understood that the variants being uncovered via genetic testing were individually rare
and uncommon. Thus, building ENIGMA as an international effort would help allow for
statistically significant data collection. As stated by the consortium, they want to ‘pool
resources, exchange methods and data and coordinately develop and apply algorithms for
the classification of BRCA1 and BRCA2’ (Spurdle et al., 2012). In addition, results are
communicated to the Breast Cancer Information Core (BIC).
A separate, more recent endeavor with regards to the classification of variants is
the Prospective Registry of Multi-Plex Testing (PROMPT). PROMPT is a registry that
aims to gather data required to comprehend the risks that are associated with VUS results
following multiplex gene testing ("PROMPT to Detail Breast Cancer Risk," 2014). Four
significant cancer institutes including the Dana-Farber Cancer Institute, Mayo Clinic,
Memorial Sloan Kettering Cancer Centre, and Abramson Cancer Centre of The
University of Pennsylvania have partnered with Ambry Genetics, GeneDx, Myriad
Genetics, Pathway Genomics, and Quest Diagnostics launch this online registry. The
patient is made aware of PROMPT via the genetic testing laboratories and it is the
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patient’s own decision whether she/he wishes to share information or not via an online
website. It has been stated that the study findings will be made public. The efforts of
PROMPT will begin with breast cancer but eventually will transcend to other cancer
syndromes. Finally, new information obtained via PROMPT will be provided directly to
patients.
Additional registries such as ClinVar also exist. ClinVar is a free and publically
accessible database whose aim is to define the relationship between genotype and
phenotype (Landrum et al., 2014). Family studies that are routinely offered to individuals
presenting with a variant are a separate but also important manner in which variants can
become reclassified. Together, the aim of all these endeavors is to enable variant cancer
genetic testing results to have significance and meaning in the clinical setting.
In addition to the complex process of reclassification, there remains a significant
question regarding who is ultimately responsible for notifying the patient if
reclassification occurs. In previous years, ACMG has released statements that help to
define the process of informing patients of reclassification. Specifically, they
recommended that the laboratory re-contact primary care physicians when updated
information regarding VUS reclassification occurs (Richards et al., 2008). This
responsibility of the laboratory may be particularly important as sequence variations
identified may be rare in the population, and it may only be single laboratories who have
knowledge of them (Richards et al., 2008). Myriad Genetic Laboratories, who have
reclassified BRCA1 and BRCA2 variants over the years, stated that ‘Amended reports are
sent weekly to healthcare providers who have patients for whom a VUS reclassification
affects their report’ (Eggington et al., 2013). However, this protocol may be challenged,
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as the increasing number of tests being ordered will lead to more VUS results and an
increasing workload. (Eggington et al., 2013).
The need to set forth clear guidelines and a working plan of who is responsible for
re-contacting the patient and primary care physician is necessary. In addition to the
laboratory, the clinic ordering testing may benefit from implementing a system whereby
they can re-contact a patient if their VUS becomes reclassified (Murray et al., 2011).
Thus, the role of the cancer genetic counselor in communicating the possibility of VUS
results and their clinical implications becomes a critical responsibility. For genetic
counselors, a primary role is to ensure that the patient is given full and thorough informed
consent prior to genetic testing.
Several researchers argue that a patient must also bear some responsibility for
future re-contact. Murray et al. (2011) cite several examples of practices that are
currently in place to address this need. For example, the patient must inform the genetic
counselor and clinic of a change of address. Others propose the patient re-contact the
clinic every one to three years for an update on whether their particular VUS has been
reclassified, while others may send a letter to the patient informing them that updated
information is available and inviting them to contact the clinic for more information.
Challenges can arise, as it can take many years for a VUS reclassification to occur. For
example, questions around who should be informed of a VUS reclassification if the
patient has passed away may be a difficulty that can be an issue. (Fecteau et al., 2014;
Murray et al., 2011) Some researchers maintain that it may be advisable to discuss this in
the session with the patient as the reclassification information could be of importance to
family members in years to come (Murray et al., 2011).

11

Research regarding genetic counseling and VUS reclassification is lacking.
Addressing some of the issues with multiplex genetic testing, such as reclassification,
now before the gap widens even more with the growing use of these panels is crucial
(Hiraki et al., 2014). A survey of 24 Canadian genetic counselors confirmed that all
would like to see guidelines relating to reclassification and further work required of the
genetic counselor (Richter et al., 2013). Also, as Mauer et al. (2011) stated, “Providers
need to be prepared for an increase in case management time and the associated longterm follow-up of these VUSs in regards to reclassification” (p. 411).
As of yet, no practice guidelines have been published to which genetic counselors
should adhere when dealing with multiplex genetic testing and VUS reclassification. This
study is intended to uncover current ‘best practices’ and identify areas for which genetic
counselors feel they need direction is of major benefit to this revolutionary field. It
therefore brings value to not only genetic counselors but also to their patients. It is
important to note that this study may have wider reaching implications, as the issue of
VUS reclassification is not unique or limited to cancer genetics only (Plon et al., 2008).
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Chapter 2: Manuscript
Variant Reclassification in Cancer Genetic Testing: Are Genetic Counselors Prepared?
A Review of Current Practices 1

1

White N.G., White B., Brooks K., & Radford C. To be submitted to Journal of Genetic Counseling.
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2.1 Abstract
Purpose: Cancer genetics has emerged as a critical specialty within the field of genetic
counseling. Advancements in research are constantly uncovering new insights into the
genetics of cancer and inherited cancer syndromes. It is crucial that genetic counselors
and the institutions in which they work are in sync with these advancements. Currently,
multiplex or multi-gene cancer testing is rapidly being adapted into the cancer genetic
counseling setting. The ‘hot topic’ of an increased likelihood of receiving variant results
following such testing has been explored in depth in the literature. However, research
surrounding genetic counseling practices and the reclassification of VUS results is
lacking. No consensus guidelines addressing variant reclassification yet exist. This study
aimed to identify current practices of genetic counselors with regard to variant
reclassification, and to explore whether genetic counselors feel they need official
guidelines relating to the reclassification of variant results.
Method: An online survey distributed through the National Society of Genetic
Counselors and the Cancer Special Interest Group (SIG) was utilized in this research
study. Statistical Analysis System (SAS) 9.4 was employed for quantitative data and
statistical analysis while qualitative data was coded and analyzed for major themes using
grounded theory methods.
Results: We determined that cancer genetic counselors are handling the reclassification
of VUS results in a unified manner. Common themes across almost 200 respondents
demonstrated that they approach benign or deleterious reclassification in a similar
fashion. 95% of respondents (n = 209) discuss variant reclassification with their patients
upon receiving a VUS result. Similarly, 95% of respondents (n = 209) will sometimes or
always make a plan to communicate VUS reclassification results should they arise in the
xiv

future. The overwhelming majority (97%) of respondents (n = 183) indicated that the
protocol for re-contacting patients with a VUS reclassification would not be different
from what they had used in the past for single-gene analysis. Varying opinions existed on
whether practice guidelines relating to VUS reclassification are necessary. The majority,
62% of respondents (n = 178), agreed or strongly agreed that there was a need for
guidelines relating to variant reclassification. Those who disagreed expressed concerns
surrounding liability issues and the feasibility of implementing recommendations across
different institutions.
Conclusions: Findings from this study indicate that most genetic counselors are utilizing
unified practices when handling the reclassification of variant results. Additionally, a
proportion of genetic counselors felt that guidance or recommendations for certain areas
relating to variant reclassification are necessary. While future research is needed to
explore more in-depth the issues and opinions identified in this research project, another
possible approach is for the NSGC Cancer SIG to address this topic at their earliest
opportunity, given the coming wave of VUS reclassifications from multiple collaborative
efforts to more urgently reclassify VUS results.
Keywords: Cancer genetics, genetic testing, multi-gene panels, multiplex genetic
testing, variant(s), VUS, reclassification
2.2 Introduction
Cancer genetics is an ever-evolving specialty within the field of genetic counseling. The
advent of next-generation sequencing technologies has allowed for the expansion of
genetic testing options for those individuals considered to be ‘high-risk’ due to personal
or family history. As a profession, genetic counselors must develop and grow alongside
15

these improvements to ensure they are capable of providing the best possible care to their
patients.
Conventionally, sequential single gene analysis has been the manner in which
genetic testing has been conducted in the cancer setting (Domchek et al., 2013; Mauer et al.,
2014). Genes that were most likely to carry a mutation based on the personal and family

history were first analyzed. However, advances in sequencing technologies now enable
the simultaneous analysis of many genes associated with cancer risk (Domchek et al.,
2013; Fecteau et al., 2014; Mauer et al., 2014; Walsh et al., 2010; Wolfe Schneider et al.,
2014). Multiplex genetic testing using next-generation sequencing (NGS) is becoming
increasingly popular and it appears to be the preference for many healthcare professionals
(Hiraki et al., 2014; LaDuca et al., 2014). However, analyzing multiple genes
concurrently brings with it unique and novel challenges. The likelihood that a variant of
uncertain significance (VUS) will be identified is increased (Domchek et al., 2013;
Hilbers et al., 2013; Wolfe Schneider et al., 2014). A VUS is a change in sequence for
which the implication on gene function is unknown.
The American College of Medical Genetics and Genomics (ACMG) recently
defined five different categories of sequence variation (1) benign; (2) likely benign; (3)
uncertain significance; (4) likely pathogenic; and (5) pathogenic (Richards et al., 2015).
With the accumulation of larger data sets the VUS rate associated with multiplex genetic
testing will decrease and in turn VUS reclassification will increase (LaDuca et al., 2014;
Mauer et al., 2014). The reclassification of VUS results conceivably could have
significant implications for a patient; the reclassification could alter the patient’s own
cancer risk assessment as well as their management options (Murray et al., 2011).
16

Reclassification may also provide family members with the ability to obtain meaningful
genetic test results, as NCCN guidelines do not recommend testing of relatives when a
VUS is identified (Murray et al., 2011).
As VUS reclassification becomes increasingly common, new practice guidelines
will perhaps be needed, to specifically address who is responsible for notifying the
patient (LaDuca et al., 2014).Previously, ACMG has recommended that laboratories recontact

primary

care

physicians

when

updated

information

regarding

VUS

reclassification occurs (Richards et al., 2008). Myriad Genetic Laboratories, state that
‘Amended reports are sent weekly to healthcare providers who have patients for whom a
variant reclassification affects their report’ (Eggington et al., 2013). In fact, we note that
these reclassification reports from this company are being sent directly to genetic
counselors (and presumably other ordering providers) rather than to patients or
physicians not listed as ordering providers (Personal communication, P. Walker, April,
2015). As reclassification efforts increase and the workload grows, current practices may
be difficult to maintain (Eggington et al., 2013).
Research into genetic counseling and VUS reclassification is lacking. Addressing
some of the issues associated with multiplex cancer genetic testing is crucial, as variant
reclassification will continue to occur, presumably at an increasing rate (Hiraki et al.,
2014). Studies indicate providers are interested in guidelines to help guide practice, but
no such guidelines exist for genetic counselors (Richter et al., 2013). This particular study
looks to identify specific areas within VUS reclassification in which genetic counselors
need direction, as well as to uncover ‘best practices’ for the handling of VUS
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reclassifications. Results may have wide reaching implications, as the issue of VUS
reclassification is not unique or limited to cancer genetics only (Plon et al., 2008).
2.3 Materials and Methods
2.3.1 Participants.
Genetic counselors that are currently offering multiplex cancer genetic testing to their
patients on an ongoing basis were eligible to participate in this study. We anticipated
minimal risk for those counselors who participated, as they were responding to questions
regarding ongoing practices in their working environment.

The following inclusion

criteria applied to the research conducted:
•

Genetic counselors working in the cancer field and offering multiplex genetic
testing

•

Cancer genetic counselors practicing in the United States

•

Cancer genetic counselors practicing in Canada who may be members of the
NSGC

While the following exclusion criteria applied:
•

Genetic counselors not currently practicing as a cancer genetic counselor

•

Cancer genetic counselors not offering multiplex genetic testing

2.3.2 Invitation to Participate.
Participants were invited to complete the study through the distribution of an online
questionnaire through the National Society of Genetic Counselors (NSGC) Cancer
Special Interest Group, as well as via an email blast to all NSGC members. Included in
the notification was an invitation letter to participate in an online questionnaire regarding
VUS reclassification. Originally flyers were distributed at the 2014 NSGC conference but
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no participants were obtained via this method of recruitment. The participants remained
completely anonymous; no identifying information was gathered unless they consented to
take part in a telephone interview. It is important to note that due to difficulty in recontacting participants no phone interviews were conducted. In addition, as a result of
time constraints a pilot study was not carried out prior to this research study going live.
2.3.3 Data Collection.
The primary method of data collection for this research project was via an online
questionnaire. The questionnaire was posted on www.surveymonkey.com and could be
accessed by going to www.surveymonkey.com/s/VUSreclassificaiton. The online
questionnaire consisted of a series of statements and questions for the participant to
consider and answer with the final section collecting demographic information. In
addition to the online survey it was originally proposed that volunteers from the
participants would be interviewed via telephone in order to allow them to share their
thoughts and opinions regarding VUS reclassification. Unfortunately, this qualitative
aspect of the research project was not completed due to a difficulty in re-contacting those
participants who had indicated that would be willing to be interviewed. The limitations of
not conducting thorough qualitative analysis in addition to analyzing the quantitative
results has been recognized and acknowledged. This research study was reviewed and
approved by the Institutional Review Board, Office of Research Compliance, of the
University of South Carolina, Columbia, SC, on August, 2014.
2.3.4 Data Analysis & Statistical Analysis.
Descriptive statistical analysis using Microsoft Office Excel software was used to address
the research goal. The majority of survey items resulted in categorical information and
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therefore percentages and frequencies could be calculated. For quantitative analysis,
Statistical Analysis System (SAS) 9.4 was used after data was transferred from Excel
spreadsheets. Inferential statistical techniques were used to make comparisons and
explore associations between variables from the survey. To assess associations between
two categorical variables, the chi-square test for independence was implemented as well
as Fisher’s Exact Test. Grounded theory methods were employed to code free-response
questions and identify emergent themes.
2.4 Results
2.4.1 Demographic Information.
An invitation to participate in the online survey was sent in an email blast to the entire
NSGC membership list, resulting in 216 responses from cancer genetic counselors. Of
those who responded a total of 176 participants provided demographic information as
seen in Table 2.1.
In addition to the demographics represented in Table 2.1, information regarding
multiplex genetic testing was obtained. Of 215 respondents, 66% order multiplex panels
at least 50% of the time. Monte Carlo Estimation for Fisher’s Exact Test found that there
was neither a statistically significant association between ordering multiplex genetic tests
and the participant’s age, (99% lower conf limit = .7737, 99% upper conf limit = .949, p
= .7843) nor a statistically significant association between ordering multiplex genetic
tests and years of work experience, (99% lower conf limit = .0967, 99% upper conf limit
= .1125, p = .1046). Respondents (n = 176) reported that TAT (48%) and limited clinical
utility (46%) are the two main reasons as to why they do not order multiplex genetic tests
in certain situations. Almost half (43%) of respondents selected ‘other’ which included
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reasons such as patient preference, known familial mutation, and specific clinical
diagnosis. A clear majority (69%) of respondents (n = 215) are not deterred by the variant
rate when ordering multiplex genetic testing and 70% of respondents (n = 216) indicated
that variant rate was not a factor that played into their decision making process. Figure
2.1 illustrates what factors are important and not important to genetic counselors when
deciding whether single gene or multiplex genetic testing is the best course of action.
Family history and patient preference are the two most important factors.

Figure 2.1 Contributing factors in respondents’ decision to order single gene tests or
multiplex genetic tests.
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Table 2.1 Participant Demographics (n = 176)
n

%

Age
20-30

93

53%

31-40

38

22%

41-50

19

11%

51-60

19

11%

61-70

7

4%

172

98%

4

2%

109

62%

5-10 years

30

17%

10 - 15 years

14

8%

15 – 20 years

11

6%

Greater than 20 years

12

7%

Academic Institution/University Hospital

61

35%

Public/Community Hospital

51

29%

Private Hospital

31

18%

Private Oncology Group

16

9%

Genetics Centre

3

2%

Laboratory

1

1%

12

7%

Less than 5

83

47%

5-10

16

9%

10 - 15

74

42%

15 - 20

3

2%

Gender
Female
Male
Years experience in the cancer field
Less than 5 years

Setting in which they practice

Other (Unspecified hospital, HMO,
federal group)
Number of panel tests ordered per
week
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2.4.2 ‘Best practices’ or commonalities employed by genetic counselors when
dealing with VUS reclassification.
Almost all (95%) of respondents (n = 183) reported that they felt genetic counselors
should always be made aware of changes in reclassification. Additionally, of 207
respondents, 89% either agree or strongly agree that patients should be made aware of
VUS reclassification regardless of what the reclassification is. Over half (59%) of
respondents (n = 183) reported that there is not a set protocol in their workplace for recontacting patients when a VUS reclassification report is received. A majority (67%) of
respondents (n = 183) would contact the patient via telephone when a benign
reclassification is received (Figure 2.2). Upon receiving a deleterious reclassification,
51% of respondents (n = 183) would notify the patient via telephone while 24% would
have an in-person appointment, and 19% of respondents selected ‘other’ (Figure 2.3).
Almost all of those who selected other reported that they would telephone the deleterious
reclassification information and follow that with an in-person appointment. Of those who
would not re-contact the patient for a benign reclassification (n = 7), two indicated that
they would not re-contact the patient for a deleterious reclassification. At the alpha = 0.5
level of significance, there is a significant association between the reported action of
genetic counselors for benign reclassification reports and deleterious reclassification
reports (Monte Carlo Estimate for Fisher Exact Test, 99% Lower Conf Limit = <.0001,
99%; Upper Conf Limit = .0005; p = < .0001).
A free response question looked to determine under what circumstances
respondents would consider non-disclosure of VUS reclassification results. The majority
of respondents could not think of any situation in which they would feel comfortable not
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disclosing VUS reclassification information. Many respondents stressed that such
information was information the patient was entitled to know.
“I don't think there are any circumstances when a clinician should
withhold information about a person's result. Even if a likely benign
variant is reclassified to a polymorphism, I want to let the patient know,
even if only for their peace of mind. Plus, it is their result and they have a
right to know what we are calling it”
“None. They deserve "results", whatever they are. I've never thought of "in case
of death" but will now ask my patient every time.”
A number of respondents did express that if the reclassification resulted in a downgrade
or did not change clinical utility nor medical management they would feel more
comfortable with non-disclosure. Other themes identified were related to patient
preference to not receive the information and barriers in re-contacting the patient.
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Figure 2.2 Primary means of discussing benign reclassification with the patient.

Figure 2.3 Primary means of discussing deleterious reclassification with the patient.
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2.4.3 Dealing with issues surrounding VUS reclassification in a session.
Participants were asked a number of questions surrounding how they deal with VUS
results and VUS reclassification in the genetic counseling session. These questions have
been shown to be reliable with similar responses for similar groups (Cronbach’s α = .70).
Nearly all, (99%) of respondents (n = 210) said that they sometimes or always discuss the
possibility of VUS results prior to consenting the patient for single gene analysis. All
respondents (n = 210) sometimes or always discussed the possibility of VUS results prior
to consenting their patients for multiplex genetic testing.
Eleven respondents indicated that they do not discuss VUS reclassification before
consenting patients for multiplex genetic testing. Of the subset of people who do not
discuss VUS reclassification prior to ordering multiplex genetic testing seven respondents
indicated that they would always discuss the reclassification of variants should a VUS
result be received. Three respondents indicated they would sometimes discuss variant
reclassification when a VUS result is received while one respondent indicated that she/he
would never discuss reclassification. Of the 209 respondents who reported they would
sometimes or always discuss variant reclassification when a VUS result is received 95%
will sometimes or always make a plan to communicate the reclassification information.
Within this plan 53% sometimes or always discuss who is to receive the reclassification
information in the event of the patient’s death.
The large majority (97%) of respondents (n = 183) indicated that the protocol for
re-contacting patients would not be different from what they had used in the past for
single-gene analysis. Participants were asked whether they felt that methods at their
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institution were working sufficiently for the handling of VUS reclassifications. For those
who answered ‘yes’, certain themes emerged. Firstly, a high proportion of respondents
felt that there are not any issues at this time as the number of VUS reclassification reports
is manageable. However, multiple participants also stated that with a bigger workload
and more VUS reclassifications the protocol in place might not stand.
"They are working sufficiently now, but we do not have a large patient population
so it has not been as thoroughly tested to find any weaknesses."
"We have not had a large number of VUS reclassified so this has not become a
volume issue"
Additionally, a set of respondents explained how the methods employed at their
institution are currently satisfactory, whether the methods are secure emails, letters, in
person appointments or yearly scheduled follow-ups for patients with a VUS result.
Genetic counselors who were setting their own protocol with regard to the handling of
VUS reclassifications expressed their satisfaction at being able to alter it as needed. Of
the respondents who indicated that methods at their institution were not working
sufficiently the majority stated that they did not have a set protocol in place or had a
limited number of VUS reclassification experiences. Commonly, the participants
declared that they are learning as they go, figuring out how to deal with VUS
reclassification reports as they gain more exposure to them. Barrier in re-contacting
patients was another theme identified as having a role in why participants felt that current
methods at their institution were not working.
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“This year we started a variant follow up program which we enter all VUS results
into we follow up with the patients every 6 months and update the lab with
changed and vice versa”
“Many variants are reclassified 10 + years after the patient had testing and it can
be difficult to get in contact with the patient if they have not provided updated
contact information through the years"
When asked to describe the ideal situation with regard to genetic counseling and the
management of VUS reclassification reports different key themes were identified as
follows:
•

Some respondents felt their current protocols worked adequately.

•

Other respondents expressed that the availability of a central database to notify
genetic counselors of reclassifications would be beneficial in reducing the burden
on them.

“Database that constantly searches for reclassifications based on input from labs
across the country and then will alert when a variant is reclassified.”
•

A number wanted all laboratories to always send VUS reclassification reports
regardless of whether the VUS was upgraded or downgraded.

“Genetic counselors shouldn't have to waste their time looking into a VUS every
year, etc. They should be able to trust that the lab will notify them if there is an
update in the VUS status.”
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•

A proportion of respondents felt the responsibility for re-contact should ideally
fall on the patient.

“Patients MUST bear the responsibility to re-contact us--we try to find them if
something needs to be conveyed, but people move/change phone
numbers/change names so often that it is simply not possible to track everyone
down. Sometimes I have trouble getting ahold of a patient we tested a few
weeks ago to give the initial results; finding them months or years or decades
after the fact is infinitely more challenging.”
2.4.4 The needs and wants of genetic counselors with regard to practice guidelines.
Over half (62%) of respondents (n = 178) agreed or strongly agreed that there was a need
for practice guidelines regarding VUS reclassifications. A proportion (30%) neither
agreed nor disagreed while 8% disagreed and do not think that practice guidelines are
necessary. Monte Carlo estimate for Fisher’s Exact Test showed no significant
association between whether the respondents felt that practice guidelines are necessary
and their workplace (99% Lower Conf Limit = .1103; 99% Upper Conf Limit = .1269; p
< .1186). There was a significant difference in belief about whether practice guidelines
should be developed between people who order multiplex genetic tests less than 50% of
the time and those who order multiplex genetic testing greater than 50% of the time (row
mean scores differ p < .0111). The Cochran-Mantel-Haenszel Statistic used to calculate
the row mean scores differ value is able to ignore the fact that twice as many people
chose ‘order more than 50% multiplex genetic testing’. Thus, those respondents who
order multiplex genetic testing less than 50% of the time agree more strongly that
practice guidelines are necessary. Respondents indicated that the most important issues to
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be addressed in practice guidelines were “who is responsible for re-contact of the patient
following

a

variant

reclassification”

and

“the

laboratories

involvement

and

responsibilities”. When asked who should be responsible for monitoring the status of a
VUS and who should be responsible for re-contacting the patient should a VUS become
reclassified, 77% of respondents (n = 183) indicated that laboratory personnel should be
responsible for the monitoring of VUS’s while 77% of respondents (n = 183) also
indicated that genetic counselors should be responsible for re-contact of the patient if a
VUS becomes reclassified. Chi-square analysis determined that there was a significant
association between these two questions (p < .0001).
A number of free response questions aimed to gain a more in depth understanding
of respondent’s thoughts and opinions regarding VUS reclassification and practice
guidelines. Many respondents felt that the issue regarding re-contacting of the patient and
the barriers associated should be addressed within guidelines. The importance of
clarifying to what extent genetic counselors must attempt to re-contact patients and what
steps to take when they cannot re-contact the patient was evident in respondents answers.
"What the GC's responsibility is in the event the patient cannot be re-contacted what is our due diligence?"
"The most important item is who is responsible. We had a situation where a
physician ordered a test and the patient had a VUS (GC was not involved).
Then the GC saw a new ovarian patient, and it was found that she was the
sister of the patient with a VUS. The GC discovered that the VUS had been
reclassified as deleterious, but the original patient with the VUS had
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switched physicians and this info fell through the cracks. When this was
discussed with both physicians, they blamed each other and neither would
take responsibility."
An additional theme identified was a need for clarification of the role of laboratories in
VUS reclassification. Many respondents expressed that although laboratories should be
responsible for monitoring the status of a VUS, not all laboratories report out all
reclassification results.
“Needs to be a guideline for all laboratories, since different labs have different
protocols and this can be confusing for counselor and patients."
“The front end of the process is most important and needs to be
standardized. Each lab must have a reliable process for reclassification
and communication to the clinician who originally ordered the test
(physician or GC). Once this information is sent to the clinician, how it's
handled from there should be fairly straightforward and can vary by
clinic.”
Finally, some respondents indicated in their free responses that no practice guidelines are
necessary. These genetic counselors either reasoned that such guidelines would set
genetic counselors up for liability issues or could not be implemented due to many
institutions and workplaces functioning uniquely.
“There should not be a practice guideline for this. It would be a law suit waiting
to happen.”
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“I think this type of guideline has the potential to set GCs up for great liability
….. I strongly encourage people to think about legal liabilities this could create
before setting a precedent and creating a guideline”
2.5 Discussion
The goal of this research study was to gain an understanding of the practices and methods
currently being employed by cancer genetic counselors in their handling of the
reclassification of VUS results. Additionally, we wanted to explore and assess both the
needs and wants of genetic counselors with regard to the management of VUS
reclassifications in the genetic counseling setting. As over half of respondents order
multiplex genetic testing at least 50% of the time in their clinical practice it was felt that
this was an appropriate population to survey regarding panel testing and issues that may
arise in the cancer setting. Additionally, the genetic counselors surveyed are clearly not
frightened by or scared of possible VUS results and variants do not seem to play an
important factor in the decision to order multiplex testing over single gene testing.
Our first aim was to understand whether genetic counselors are employing similar
practices across the board for the management of VUS reclassifications, despite a lack of
guidelines. Unexpectedly, we determined that genetic counselors do appear to be
applying standard procedures when it comes to VUS reclassifications. Common practices
are being utilized. The majority of genetic counselors surveyed would telephone a patient
with a benign reclassification while more genetic counselors felt an in-person
appointment was appropriate for a deleterious reclassification. Similar observations were
made in a recent study that looked at genetic counseling practices for VUS and VUS
32

reclassifications that arise due to BRCA testing. In their study population of 410 genetic
counselors, the majority call the patient and mail benign VUS reclassifications while for
deleterious reclassifications the majority also met the person face to face (Scherr, Lindor,
Malo, Couch, & Vadaparampil, 2015).
Overall, it does appear that common practice is to inform patients of any
reclassification, regardless of its status, as the large majority of respondents expressed
how a reclassification result was information the patient was entitled to and had a right to
know. Cancer genetic counselors appear to have a strong feeling that they are not
gatekeepers of information and that test results, regardless of their meaning, are the
patient’s property.
Despite genetic counselors employing common practices, the majority of
respondents indicated that their workplace did not have a set protocol for the handling of
VUS reclassifications. A number of respondents expressed how they were formulating
procedures to handle reclassifications as they go. Although this currently seems to be
sufficient, with a larger workload likely over the course of time it must be considered that
not having a set protocol could be detrimental. At present the workload is manageable but
for many the methods they are employing have not yet been rigorously tested as to their
limits and therefore may prove troublesome in the future. Several respondents expressed
this same sentiment in open-ended responses. Therefore, genetic counselors must begin
to think ahead to ensure that in the future their methods will continue to work
sufficiently, otherwise, it could likely impact patient care.
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Next, it was important for us to understand the manner in which genetic
counselors handle VUS reclassifications during the genetic counseling session itself.
Again, global similarities in practices were observed. In our population, it is standard of
practice to discuss the possibility of VUS results prior to conducting genetic testing; all
respondents stated they sometimes or always do this before both single gene and
multiplex genetic testing. For the purpose of this study we were interested in whether the
reclassification of VUS results was also included in this discussion as a standard of
practice. VUS reclassification is something that genetic counselors appear to think about
and see as an important factor to discuss prior to conducting testing. Only 11 of 210
respondents do not talk about reclassification of variants before conducting multiplex
genetic testing. Three of these 11 respondents will only sometimes talk about
reclassification when a VUS result is received, while one respondent will never talk about
reclassification upon receiving a VUS result. This study did not specifically assess what
genetic counselors include in their discussion about VUS reclassification but it was
determined that 95% of those who talk about reclassification in the genetic counseling
session make a plan to communicate reclassification information should it become
available in the future. It has previously been discussed in the literature that due to the
average time (typically in years) it takes for a VUS to become reclassified, a discussion
surrounding who should receive reclassification information in the event of the patient’s
death should be broached by the genetic counselor (Murray et al., 2011). We did not
expect the majority of genetic counselors to be doing this; however, approximately half
indicated they were including this in their discussions with the patient.
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Finally, we explored in-depth what areas genetic counselors feel they need
guidance with or clarification of in terms of VUS reclassification. Furthermore, we
wanted to investigate whether genetic counselors feel a need for specific practice
guidelines relating to this topic. Interestingly, it appears that a majority of the genetic
counselors surveyed feel that they are prepared for VUS reclassification if and when it
arises, for many it may simply mean an extension of practice that they are already
familiar with through single gene analysis. Most agreed or strongly agreed that practice
guidelines regarding VUS reclassification are needed, while a proportion did not have an
opinion either way. We further analysed the data to determine whether those ordering a
larger proportion of multiplex genetic tests were either more for or against practice
guidelines. The proportion of people who disagreed with the statement ‘There is a need
for practice guidelines regarding VUS reclassification and how the reclassification of
VUS results should be handled by genetic counselors’ was higher in those who ordered
multiplex genetic tests more than 50% of the time in their clinical practice and vice versa,
a higher proportion of those who order multiplex genetic tests less than 50% of the time
more strongly agreed with the statement. Perhaps, genetic counselors with more
experience and knowledge regarding multiplex genetic testing and the handling of related
issues do not see VUS reclassifications as an area within cancer genetics that requires
specific guidelines. Those with less experience who feel they need clear guidance may
benefit from further education or management tips on how to handle VUS
reclassifications rather than guidelines themselves. Some respondents disagreed and felt
practice guidelines are unnecessary. Liability and the possibility of lawsuits was a
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concern for some while others felt that guidelines could not be implemented across all
institutions. Both of these topics are valid concerns that we had not previously identified.
An issue that has been discussed in other literature is the barrier that can arise in
re-contacting a patient when a VUS is reclassified (Murray et al., 2011). In this study,
this too was identified as an area of concern for genetic counselors. Precisely,
respondents recognized that barriers in re-contacting patients may exist and questioned to
what lengths must the genetic counselor go in order to contact the patient. A critical
question we identified was when barriers in re-contacting arise, at what point is it no
longer the responsibility of the genetic counselor to inform the patient of the
reclassification information? An additional area identified as being of concern to
respondents was the laboratories involvement and responsibilities. For respondents, this
was identified as the second most important topic to be included in any guidelines
relating to VUS reclassification. Genetic counselors felt strongly that the laboratories are
responsible for the monitoring of variant states; however, many expressed unease due to
laboratories each having different protocols. The unease and confusion seemed to lie with
the fact that there are no standards for variant communication across the many
laboratories performing clinical genetic analysis of cancer genes. It remains to be seen
whether guidelines for the genetic counseling practice could influence or dictate
laboratory standardization.
Study Limitations
There are several important study limitations to consider. First, a recognized limitation of
this study is that many of the participants have not yet had to deal with a large number of
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VUS reclassifications in their clinical practice. Importantly, a proportion of respondents
have never received a VUS reclassification. Thus, it is possible that their responses to
questions surrounding whether systems in place are working sufficiently or not will
change in the future upon receiving more VUS reclassifications. Secondly, a potential
limitation may be that the majority of participants had less than five years experience
working in the cancer field. Finally, despite having a total of 216 participants, a number
of questions, for reasons unknown were skipped by a significant number of respondents
and henceforth were not as amenable to statistical analysis. This is particularly true for
the demographics portion of the survey.
Directions for Future Research
Future research is needed to delve deeper into the observations made by this preliminary
study and ensure genetic counselors are well prepared for the reclassification of VUS
results. As this area is moving at such a breakneck pace, it is plausible to reason that
should this survey be re-administered in six months time the answers and opinions of
respondents may have changed. A reasonable ‘next-step’ would be to conduct in-depth
qualitative analysis through interviewing cancer genetic counselors. Such research would
allow for the thorough exploration of opinions and thoughts surrounding this topic that
may not have been expressed nor explored through the online survey employed in this
study. Specifically, we now know that genetic counselors discuss VUS reclassification
with their patients so it would therefore be highly beneficial to determine the particular
details about reclassification that are explained. Furthermore, it would be of interest to
determine the details of the plan to communicate reclassification that is set up between
the genetic counselor and their patient. Finally, we feel that it may be useful to gain an
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understanding of how genetic counselors and the institutions in which they work keep
track of their patients who have received VUS results in the past; this study did not assess
this question. Advancing our knowledge in all these areas would help the genetic
counseling profession reach a consensus in relation to the genetic counselors’ role and
responsibilities with regard to VUS reclassification results.
2.6 Conclusions
To our knowledge the genetic counseling community has not yet explored in depth the
genetic counselors role and responsibilities with regard to VUS reclassification.
Therefore, we believe this study to be of great value to our profession.
Unexpectedly, this research study revealed that cancer genetic counselors across
the board are currently employing similar methods in their handling of VUS
reclassification results. As a whole they feel that reclassification results are important
information for the patient to be aware of and a topic that is essential in the discussion
surrounding multiplex cancer genetic testing. Despite this, we feel that cancer genetic
counselors may not be completely prepared for an increase in the number of
reclassification results and workload expected in the future. Mauer et al. (2011) have
previously highlighted a need for providers to be prepared for such an increase in
workload. Many participants are learning as they go without any set protocol in place for
when a reclassification result is received.
Additionally, we propose that this study highlights the need for guidelines or
recommendations surrounding the role and responsibilities of the genetic counselor with
regard to VUS reclassification. Similar to findings that Richter et al. (2013) identified, the
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majority of our study participants feel that guidelines would be both beneficial and
useful. However, we are now aware of some important concerns regarding the possible
implications of guidelines that require further in depth analysis.
Additional research into VUS reclassification and the role and responsibilities of
the genetic counselor is warranted. We propose that thorough qualitative analysis which
fully explores cancer genetic counselors’ opinions, reservations and suggestions relating
to VUS reclassification be conducted. Given additional studies, perhaps a Working
Committee of the NSGC Cancer Special Interest Group (Cancer SIG) could be convened
to consider the totality of information and propose a draft guideline (if needs for a
guideline are confirmed), requesting input and comments from practicing cancer genetic
counselors prior to finalization. Subsequent studies that expand on the knowledge gained
through this research would be hugely beneficial to the genetic counseling community,
and in turn, beneficial to their patients.
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Chapter 3. Conclusions
To our knowledge the genetic counseling community has not yet explored in depth the
genetic counselors role and responsibilities with regard to VUS reclassification.
Therefore, we believe this study to be of great value to our profession
Unexpectedly, this research study revealed that cancer genetic counselors across
the board are currently employing similar methods in their handling of VUS
reclassification results. As a whole they feel that reclassification results are important
information for the patient to be aware of and a topic that is essential in the discussion
surrounding multiplex cancer genetic testing. Despite this, we feel that cancer genetic
counselors may not be completely prepared for an increase in the number of
reclassification results and workload expected in the future. Mauer et al. (2011) have
previously highlighted a need for providers to be prepared for such an increase in
workload. Many participants are learning as they go without any set protocol in place for
when a reclassification result is received.
Additionally, we propose that this study highlights the need for guidelines or
recommendations surrounding the role and responsibilities of the genetic counselor with
regard to VUS reclassification. Similar to findings that Richter et al. (2013) identified, the
majority of our study participants feel that guidelines would be both beneficial and
useful. However, we are now aware of some important concerns regarding the possible
implications of guidelines that require further in depth analysis.
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Additional research into VUS reclassification and the role and responsibilities of
the genetic counselor is warranted. We propose that thorough qualitative analysis which
fully explores cancer genetic counselors’ opinions, reservations and suggestions relating
to VUS reclassification be conducted. Given additional studies, perhaps a Working
Committee of the NSGC Cancer Special Interest Group (Cancer SIG) could be convened
to consider the totality of information and propose a draft guideline (if needs for a
guideline are confirmed), requesting input and comments from practicing cancer genetic
counselors prior to finalization. Subsequent studies that expand on the knowledge gained
through this research would be hugely beneficial to the genetic counseling community,
and in turn, beneficial to their patients.
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Appendix A: Invitation Letter to Potential Participants
Dear Potential Participant:
You are invited to take part in a graduate research study focusing on variant
reclassification in cancer genetic counseling. I am a graduate student in the genetic
counseling program at the University of South Carolina School of Medicine. My
research looks at whether cancer genetic counselors are preparing themselves for the
work that will come with an increase in the number of variants that become
reclassified. The research involves taking a survey that can be found at
www.surveymonkey.com/s/VUSreclassification.
The survey proposes a number of questions and asks your opinion on different matters
relating to multi-gene panel testing and variant reclassification. If you do not wish to
answer a certain question, please skip that question and continue with the rest of the
survey.
All responses from the surveys will be kept anonymous and confidential. We only
ask for your name and phone number in the event that you are interested in providing
more information at a later date over the phone. It is not necessary that you provide
this information. The results of this study might be published or presented at scientific
meetings; however, your answers will not be identified in any way. The survey
should take about 15-20 minutes to complete.
Your participation in this research is voluntary. By completing the survey, you are
consenting that you have read and understand this information. At any time, you may
withdraw from the study by not completing the survey.
Thank you for your time and consideration for taking part in this study. Your
answers may help genetic counselors gain much needed guidance and provide the best
care for their patients with regard to cancer panel testing and variant reclassification.
If you have any questions about this research, you may contact either me or my
advisor, Brook White, MS, CGC, at the information below. If you have any questions
about your rights as a research member, you may contact the Office of Research
Compliance at the University of South Carolina at (803)777-7095.
Sincerely,
Niamh White, B.A (Mod) in Human Genetics
Master of Science Candidate
University of South Carolina School of Medicine
USC Genetic Counseling Program
Two Medical Park, Suite 208
Columbia, SC 29203
nwhite4321@gmail.com
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(843) 754-3905
Brook White, MS, CGC
Genetic Counselor
Levine Cancer Institute
1021 Morehead Medical Dr.
Charlotte, NC 28203
Brook.White@carolinas.org
(980) 442-200
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Appendix B: Online Survey

1. What percent of genetic tests that you order are multi-gene tests?
□ 0% □ 1-25% □ 25-50% □ 50-75%

□ 75-100%

2. When you do not order multi-gene tests, why not (check all that apply)
□ Institutional protocol
□ High rate of variants
□ Guidelines do not recommend
□ Expense or Insurance
□ Limited Clinical Utility
□ Turn around time
□ Other (Please explain)
3. Does the variant rate deter you from ordering next generation sequencing
and/or panel tests?
□ Yes

□ No

Please elaborate
4. What do you consider to be a high variant rate?
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5. If you order both single gene and multi gene, panel testing, what factors
contribute to the decision to order one over the other (check all that apply)
□ Family history
□ Potential Liability
□ Insurance coverage
□ Variant rate
□ Turn around time
□ Patient preference
□ Other (Please explain)
6. You discuss the possibility of variants and uncertain tests results in a session
prior to conducting single gene/single site sequence analysis
□ Never

□ Sometimes

□ Always

7. You discuss the possibility of variants and uncertain test results in a session
prior to conducting next generation sequencing and/or panel testing
□ Never

□ Sometimes

□ Always

8. Variant reclassification is discussed in a session prior to conducting next
generation sequencing and/or panel testing
□ Never

□ Sometimes

□ Always

9. If a VUS is received, variant reclassification is discussed during result
disclosure
□ Never

□ Sometimes

□ Always

10. In this discussion a plan to communicate reclassification information is
determined
□ Never

□ Sometimes

□ Always
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11. You discuss who is to receive the reclassification information in the event of
the patients death
□ Never

□ Sometimes

□ Always

12. Variant reclassification is information that the patient should be made aware
of only if the variant has been reclassified as deleterious
□ Strongly Disagree
□ Agree

□ Disagree
□ Neither Agree nor Disagree
□ Strongly Agree

13. Variant reclassification is information that the patient should be made aware
of regardless of what the reclassification status is
□ Strongly Disagree
□ Agree

□ Disagree
□ Neither Agree nor Disagree
□ Strongly Agree

14. Under what other circumstances would you consider non-disclosure of variant
reclassification as appropriate?
15. In your workplace is there a set protocol to re-contact a patient with a variant
reclassification for a VUS
□ Yes

□ No

16. If you order multi-gene panels will the protocol for contacting the patient with
a VUS be different than what you have used in the past? Please explain.
□ Yes

□ No

17. If you have a protocol for NGS multi-gene panels, is your primary means of
discussing benign reclassification with the patient
□ Telephone
□ Mail
□ In person appointment
□ Notify physician
□ Do not re-contact
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□ Other
18. What is your primary means of discussing a deleterious reclassification with
the patient
□ Telephone
□ Mail
□ In person appointment
□ Notify physician
□ Do not re-contact
□ Other (Please explain)

19. Are the methods employed at your institution working and sufficient? Please
explain why/why not.
□ Yes

□ No

20. Given time and resources what would be the ideal situation with regards to
genetic counseling and the management of variant reclassification
21. There is a need for official practice guidelines regarding variant
reclassification and how the reclassification of variants should be handled by
genetic counselors.
□ Strongly Disagree
□ Agree

□ Disagree
□ Neither Agree nor Disagree
□ Strongly Agree

22. Part A. With regard to practice guidelines what should be included? Please
list in order of importance (1 being most important and 6 being least
important)
□ what to discuss regarding variant reclassification in the counseling session
□ who is responsible for re-contact of the patient following a variant
reclassification
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□ steps to ensure a reliable tracking system
□ procedure to be followed dependent on each specific situation (i.e. variant
reclassified as benign compared to a variant reclassified as deleterious)
□ the laboratories involvement and responsibilities
□ what to do if a patient cannot be re-contacted
Part B. In your opinion what is important for you to be included in practice
guidelines?
23. Who should be responsible for actively monitoring the status of a variant and
its reclassification?
□ Patient
□ Primary Care Physician
□ Referring Physician
□ Genetic Counselor
□ Laboratory Personnel
□ Other (Please explain)
24. Whose duty should it be to re-contact the patient should a variant become
reclassified? (Please mark with an X).
□ Primary Care Physician
□ Referring Physician
□ Genetic Counselor
□ Laboratory Personnel
□ Other (Please explain)
25. Genetic counselors should be made aware of changes in reclassification
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□ Always

□ Only when the reclassification is deleterious

□ Never

26. What is the greatest barrier that you see arising in terms of re-contact of a
patient after a variant has been reclassified?
□ Genetic counseling time and resources
□ Cannot find the patient
□ Genetic counselor not being notified of the reclassification
□ Other (Please explain)
Please answer the following questions about yourself.
27. What is your age?
□ 20-30 □ 31-40

□ 41-50

□ 51-60

□ 61-70

28. What is your gender?
□ Male

□ Female

29. For how many years have you worked in the cancer field?
□ less than 5 years
□ 5-10 years
□ greater than 20 years

□ 10-15 years

□ 15-20 years

30. Where do you practice (university hospital, private oncology group etc.)
31. Approximately how many gene panel tests do you order in a typical week?
□ less than 5

□ 5-10

□ 10-15

53

□ 15-20

